Elite Journal of HIV. Volume 2 issue 3(2024), Pp. 27-41
https://epjournals.com/journals/EJHIV

Early Infant Diagnosis: Fortifying Efforts to Stop HIV in Newborns

*Emmanuel Ifeanyi Obeagu[1], Elham Ali Ibrahim Elamin[2] and Getrude Uzoma Obeagu[3]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda

[2]Hematology and Immunohematology, Faculty of Medical Laboratory Sciences, University of ElImam EI Mahdi, Sudan

[3]School of Nursing Science, Kampala International University, Uganda

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Early infant diagnosis (EID) is an essential aspect of HIV prevention strategies, particularly in the context of mother-to-child transmission (MTCT). This review assesses the significance of EID in halting the spread of HIV to newborns, exploring current methodologies, challenges, and recent advancements. Timely diagnosis through EID facilitates prompt initiation of antiretroviral therapy (ART) and other interventions critical for improving health outcomes in HIV-exposed infants. Despite progress, barriers to effective EID implementation persist, including limited access to testing facilities and stigma surrounding HIV/AIDS. However, innovations in technology and programmatic approaches offer promise in overcoming these challenges. Strengthening EID programs is imperative for achieving the goal of ending pediatric HIV/AIDS and ensuring the well-being of newborns worldwide.

Keywords: *Early Infant Diagnosis, HIV, Newborns, Prevention, Treatment, Antiretroviral Therapy*

Introduction

The global effort to combat HIV/AIDS has made significant strides in recent decades, yet the transmission of HIV from mother to child remains a persistent challenge, particularly in resource-

Citation: Obeagu EI, Elamin EAI, Obeagu GU. Early Infant Diagnosis: Fortifying Efforts to Stop HIV in Newborns. Elite Journal of HIV, 2024; 2(3): 27-41

limited settings. Mother-to-child transmission (MTCT) accounts for a substantial proportion of pediatric HIV infections, highlighting the urgent need for effective prevention and intervention strategies. Early Infant Diagnosis (EID) emerges as a crucial component in this endeavor, offering a window of opportunity to identify HIV-positive infants promptly and initiate timely interventions to improve health outcomes. By detecting HIV infection early in infancy, EID facilitates the prompt initiation of antiretroviral therapy (ART), which has been shown to significantly reduce the risk of disease progression and mortality among HIV-infected infants. Despite the proven efficacy of EID in preventing HIV-related morbidity and mortality in infants, its implementation faces multifaceted challenges. Access to EID services remains limited, particularly in remote and underserved areas where the burden of HIV is often highest. Furthermore, logistical barriers such as the transportation of samples and the dissemination of test results pose significant hurdles to timely diagnosis and treatment initiation. Additionally, stigma and discrimination surrounding HIV/AIDS continue to deter caregivers from seeking EID services for their infants, further exacerbating the challenge of identifying HIV-positive infants early in their lives.[1-31]

In recent years, there have been notable advancements in EID technology and programmatic approaches aimed at addressing these challenges. Innovations such as point-of-care testing and the integration of EID services into maternal and child health programs have shown promise in improving access to testing and reducing turnaround times for results. Moreover, decentralized testing services and task-shifting to community health workers have emerged as strategies to enhance EID coverage, particularly in resource-constrained settings. These innovations underscore the importance of adapting EID strategies to the specific needs and contexts of different populations to maximize their impact in preventing pediatric HIV/AIDS. As the global community strives towards the ambitious goal of ending pediatric HIV/AIDS, strengthening EID programs is paramount. By overcoming barriers to access, addressing stigma, and leveraging technological and programmatic innovations, EID has the potential to play a transformative role in preventing HIV transmission in newborns and improving the health outcomes of HIV-exposed infants.[32-46] This review aims to delve deeper into the significance of EID in fortifying efforts to stop HIV transmission in newborns, exploring current methodologies, challenges, advancements, and the critical importance of timely diagnosis and intervention in this ongoing battle against pediatric HIV/AIDS.

Methodologies for Early Infant Diagnosis

Early Infant Diagnosis (EID) of HIV encompasses a range of methodologies tailored to detect the presence of the virus in infants born to HIV-positive mothers. These methodologies are crucial for identifying infected infants promptly, enabling timely initiation of interventions to mitigate the progression of the disease and improve health outcomes. Several approaches are employed in EID, each with its advantages and limitations. **Nucleic Acid Amplification Tests (NAATs)**, including polymerase chain reaction (PCR) and real-time PCR, are widely regarded as the gold standard for EID due to their high sensitivity and specificity. These tests detect HIV viral nucleic acids in blood samples, allowing for early detection of infection even in the absence of detectable antibodies. PCR-based assays offer excellent accuracy, making them particularly suitable for diagnosing HIV

in infants younger than 18 months who may still carry maternal antibodies. **Point-of-Care (POC) Tests** offer rapid results at the point of care, making them invaluable in settings where access to laboratory facilities is limited. These tests typically utilize finger-prick blood samples and provide results within a short timeframe, allowing for immediate clinical management decisions. While POC tests may sacrifice some sensitivity compared to laboratory-based assays, their speed and ease of use make them indispensable in resource-limited settings, where timely diagnosis is paramount.[47-71]

Dried Blood Spot (DBS) Testing involves collecting small blood samples on filter paper, which are then transported to laboratories for analysis. This method offers several advantages, including ease of sample collection, minimal requirements for sample storage and transportation, and the ability to test multiple samples simultaneously. DBS testing is particularly well-suited for EID programs in remote or resource-limited settings, where infrastructure for sample transportation and storage may be lacking. **Next-Generation Sequencing (NGS)** technologies have emerged as a powerful tool in HIV diagnostics, offering enhanced sensitivity and the ability to detect viral drug resistance mutations. NGS allows for the comprehensive characterization of HIV genomes from clinical samples, enabling the identification of diverse viral strains and the monitoring of viral evolution over time. While still primarily used in research settings, NGS holds promise for improving the accuracy and precision of EID in the future. Serological assays detect HIV-specific antibodies or antigens in infant blood samples. While these tests are less commonly used for EID due to the persistence of maternal antibodies in infants born to HIV-positive mothers, they can be valuable in confirming HIV infection in older infants (>18 months) who have cleared maternal antibodies. Serological assays may also be employed in conjunction with molecular testing to improve diagnostic accuracy.[72-93]

Challenges in EID Implementation

Despite the critical importance of Early Infant Diagnosis (EID) in identifying HIV-infected infants promptly and initiating timely interventions, several challenges hinder the effective implementation of EID programs. One of the primary challenges in EID implementation is the limited availability of testing facilities, particularly in rural and remote areas where the burden of HIV may be highest. Many health facilities lack the necessary infrastructure, equipment, and trained personnel to perform EID tests, leading to disparities in access to testing services. This lack of accessibility impedes early diagnosis and delays the initiation of life-saving interventions. Logistical challenges, including the transportation of samples and the dissemination of test results, pose significant barriers to timely diagnosis and treatment initiation. In resource-limited settings, inadequate transportation networks and long turnaround times for test results can further delay the identification of HIV-infected infants and the initiation of antiretroviral therapy (ART). Improving logistics infrastructure and streamlining sample collection and result delivery processes are critical to overcoming these challenges.[94-104]

The cost of diagnostic tests for EID, particularly molecular assays like polymerase chain reaction (PCR), can be prohibitive in resource-constrained settings. High testing costs limit the scalability

of EID programs and may prevent health facilities from offering testing services to all HIV-exposed infants.[105-106] Cost-effective strategies, such as pooled testing and negotiations for reduced pricing with manufacturers, are needed to make EID more accessible and sustainable in low-resource settings. Stigma and discrimination surrounding HIV/AIDS remain significant barriers to EID implementation. Fear of social ostracism and discrimination may deter caregivers from seeking testing and treatment for their infants, particularly in communities where HIV/AIDS is highly stigmatized. Addressing stigma through community education and awareness campaigns is essential to increase uptake of EID services and reduce barriers to care for HIV-exposed infants and their families. Loss to follow-up poses a challenge to the continuity of care for HIV-exposed infants undergoing EID testing. Many infants who are tested for HIV may not receive their results or may fail to return for confirmatory testing and treatment initiation. Strengthening follow-up systems, integrating EID services into routine maternal and child health programs, and engaging community health workers in tracing and retaining patients in care are critical strategies to mitigate loss to follow-up and improve outcomes for HIV-exposed infants.

Advancements and Innovations

The field of Early Infant Diagnosis (EID) of HIV has witnessed significant advancements and innovations in recent years, aimed at overcoming barriers to testing and improving the accuracy, accessibility, and efficiency of diagnostic processes.[107-108] These innovations hold great promise for enhancing EID programs and ultimately reducing the burden of pediatric HIV/AIDS. **Point-of-Care (POC) Testing** has emerged as a game-changer in EID, offering rapid and decentralized diagnostic capabilities at the point of care. POC tests, such as rapid nucleic acid tests and rapid antibody assays, provide results within minutes, enabling immediate clinical management decisions. These tests are particularly valuable in resource-limited settings where access to laboratory facilities is limited, allowing for timely diagnosis and treatment initiation even in remote areas. **Dried Blood Spot (DBS) Testing** has revolutionized sample collection and transportation for EID programs. By allowing blood samples to be collected on filter paper and transported at ambient temperatures, DBS testing eliminates the need for cold chain storage and simplifies logistics, particularly in settings with limited infrastructure. DBS testing also facilitates batch testing, enabling laboratories to process multiple samples simultaneously and improve testing throughput.

Integrating EID services into existing maternal and child health programs has been instrumental in expanding access to testing and improving coverage.[107] By incorporating EID into routine postnatal care visits, antenatal care, and immunization clinics, health systems can reach more HIV-exposed infants and streamline the testing process. Integration also facilitates the linkage of HIV-positive infants to care and treatment services, ensuring continuity of care beyond diagnosis. Task-shifting initiatives empower a broader range of healthcare workers, including nurses and community health workers, to perform EID testing and counseling. By decentralizing testing services and expanding the cadre of trained personnel, task-shifting programs increase access to EID in underserved areas and reduce the burden on specialized laboratory staff. Comprehensive training programs ensure that healthcare workers are equipped with the skills and knowledge to

perform EID testing accurately and confidently. Advances in molecular diagnostics, including next-generation sequencing (NGS) and digital PCR, offer enhanced sensitivity and specificity for detecting HIV in infants. NGS technologies enable comprehensive characterization of viral genomes, facilitating the identification of drug resistance mutations and guiding personalized treatment strategies. Digital PCR platforms provide ultrasensitive detection of low viral loads, improving diagnostic accuracy and reducing the risk of false-negative results in infants with early HIV infection.

The Role of Timely Diagnosis in Prevention and Treatment

Timely diagnosis through Early Infant Diagnosis (EID) plays a pivotal role in preventing mother-to-child transmission (PMTCT) of HIV and improving health outcomes for HIV-exposed infants.[105] The timely identification of HIV-infected infants enables healthcare providers to initiate prompt interventions, including antiretroviral therapy (ART) and preventive measures, to mitigate the progression of the disease and reduce morbidity and mortality. Timely diagnosis allows for the prompt initiation of antiretroviral therapy (ART) in HIV-infected infants, which is critical for suppressing viral replication, preserving immune function, and preventing disease progression. Early initiation of ART has been shown to significantly reduce the risk of mortality and morbidity in HIV-infected infants, improving long-term outcomes and quality of life. Early diagnosis through EID enables the implementation of preventive interventions for HIV-exposed infants, including cotrimoxazole prophylaxis, nutritional support, and breastfeeding counseling. These interventions are essential for reducing the risk of opportunistic infections, promoting optimal growth and development, and ensuring the overall well-being of HIV-exposed infants. Timely diagnosis facilitates regular monitoring of infant health and development, allowing healthcare providers to identify and address any emerging health concerns promptly. Close monitoring of HIV-exposed infants enables early detection of complications, timely adjustments to treatment regimens, and provision of appropriate supportive care, thereby optimizing health outcomes and quality of life.

Timely diagnosis of HIV infection in infants not only benefits the affected child but also contributes to the prevention of secondary transmission within the community. By identifying HIV-infected infants early and initiating ART promptly, healthcare providers can reduce the viral load in infected infants, thereby lowering the risk of transmission to other individuals, including siblings and caregivers. Early diagnosis through EID allows for long-term prognosis assessment and continuity of care for HIV-infected infants. Close follow-up monitoring and adherence to ART regimens are essential for maintaining viral suppression, preserving immune function, and preventing disease progression over time. Additionally, early engagement with comprehensive HIV care and support services promotes optimal health outcomes and quality of life for HIV-infected infants throughout their lifespan.[107]

Conclusion

Early Infant Diagnosis (EID) stands as a cornerstone in the global efforts to prevent mother-to-child transmission (PMTCT) of HIV and reduce the burden of pediatric HIV/AIDS. This review

has highlighted the pivotal role of timely diagnosis in improving health outcomes for HIV-exposed infants and contributing to the goal of eliminating pediatric HIV/AIDS. Despite challenges such as limited access to testing facilities, logistical constraints, and stigma surrounding HIV/AIDS, significant advancements and innovations have been made in EID. Point-of-care testing, molecular diagnostics, optimized testing algorithms, integrated service delivery models, and digital health technologies have revolutionized the way HIV-exposed infants are tested and managed, offering promise for improved access, accuracy, and efficiency in EID programs.

Moreover, the importance of timely diagnosis in initiating interventions such as antiretroviral therapy (ART), preventive measures, monitoring of infant health, and prevention of secondary transmission cannot be overstated. Timely identification of HIV-infected infants enables healthcare providers to intervene early, thereby improving long-term outcomes and quality of life for HIV-exposed infants and contributing to the broader public health goal of ending pediatric HIV/AIDS. To maximize the impact of EID, concerted efforts are needed to address existing challenges, scale up innovative approaches, and strengthen EID programs globally. This requires collaboration among policymakers, healthcare providers, community organizations, and other stakeholders to ensure equitable access to testing and comprehensive care for all HIV-exposed infants, regardless of geographic location or socioeconomic status.

References

1. Vrazo AC, Sullivan D, Phelps BR. Eliminating mother-to-child transmission of HIV by 2030: 5 strategies to ensure continued progress. Global Health: Science and Practice. 2018;6(2):249-256.
2. Torpey K, Kabaso M, Kasonde P, Dirks R, Bweupe M, Thompson C, Mukadi YD. Increasing the uptake of prevention of mother-to-child transmission of HIV services in a resource-limited setting. BMC health services research. 2010; 10:1-8.
3. Ogbolu Y, Iwu EN, Zhu S, Johnson JV. Translating research into practice in low-resource countries: Progress in prevention of maternal to child transmission of HIV in Nigeria. Nursing Research and Practice. 2013.
4. Adetokunboh OO, Oluwasanu M. Eliminating mother-to-child transmission of the human immunodeficiency virus in sub-Saharan Africa: The journey so far and what remains to be done. Journal of infection and public health. 2016;9(4):396-407.
5. Yah CS, Tambo E. Why is mother to child transmission (MTCT) of HIV a continual threat to new-borns in sub-Saharan Africa (SSA). Journal of infection and public health. 2019;12(2):213-223.
6. Vrazo AC, Sullivan D, Phelps BR. Eliminating mother-to-child transmission of HIV by 2030: 5 strategies to ensure continued progress. Global Health: Science and Practice. 2018 Jun 27;6(2):249-56.
7. Johri M, Ako-Arrey D. The cost-effectiveness of preventing mother-to-child transmission of HIV in low-and middle-income countries: systematic review. Cost Effectiveness and Resource Allocation. 2011; 9:1-6.

Citation: Obeagu EI, Elamin EAI, Obeagu GU. Early Infant Diagnosis: Fortifying Efforts to Stop HIV in Newborns. Elite Journal of HIV, 2024; 2(3): 27-41

8. Idele P, Hayashi C, Porth T, Mamahit A, Mahy M. Prevention of mother-to-child transmission of HIV and paediatric HIV care and treatment monitoring: from measuring process to impact and elimination of mother-to-child transmission of HIV. AIDS and Behavior. 2017; 21:23-33.
9. Mutabazi JC, Zarowsky C, Trottier H. The impact of programs for prevention of mother-to-child transmission of HIV on health care services and systems in sub-Saharan Africa-A review. Public health reviews. 2017; 38:1-27.
10. Oladele EA, Khamofu H, Asala S, Saleh M, Ralph-Opara U, Nwosisi C, Anyaike C, Gana C, Adedokun O, Dirks R, Adebayo O. Playing the catch-up game: accelerating the scale-up of prevention of mother-to-child transmission of HIV (PMTCT) services to eliminate new pediatric HIV infection in Nigeria. PloS one. 2017;12(1): e0169342.
11. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health. 2024;2(1):52-61.
12. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
13. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. Madonna University journal of Medicine and Health Sciences. 2023;3(1):13-18. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93.
14. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
15. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
16. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
17. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
18. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. Int. J. Curr. Res. Med. Sci. 2023;9(2): 1-5.DOI: 10.22192/ijcrms.2023.09.02.001
19. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
20. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community

Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
21. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
22. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
23. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
24. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
25. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
26. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
27. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
28. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
29. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;130. links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf.

30. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.
31. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
32. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
33. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
34. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
35. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
36. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
37. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
38. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
39. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-

knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf

40. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
41. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
42. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
43. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian Journal of Dental and Health Sciences. 2023;3(2):7-14. http://ajdhs.com/index.php/journal/article/view/39.
44. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
45. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
46. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.
47. Bianchi F, Cohn J, Sacks E, Bailey R, Lemaire JF, Machekano R, Nzima VN, Ekouévi PF, Makone M, Odhiambo CO, Chadambuka A. Evaluation of a routine point-of-care intervention for early infant diagnosis of HIV: an observational study in eight African countries. The lancet HIV. 2019;6(6): e373-81.

48. Jean-Philippe P, Spiegel H, Gnanashanmugam D, Fitzgibbon J, D'Souza P, Crawford KW, Jayashankar L, Bacon MC, Essajee SM, Aldrovandi GM, Cotton M. HIV birth testing and linkage to care for HIV-infected infants. Aids. 2017;31(13):1797-1807.
49. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Steven PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. Asian Journal of Research in Infectious Diseases. 2022;10(4):1-7.
50. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
51. Igwe MC, Obeagu EI, Ogbuabor AO. ANALYSIS OF THE FACTORS AND PREDICTORS OF ADHERENCE TO HEALTHCARE OF PEOPLE LIVING WITH HIV/AIDS IN TERTIARY HEALTH INSTITUTIONS IN ENUGU STATE. Madonna University journal of Medicine and Health Sciences. 2022;2(3):42-57. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75.
52. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
53. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
54. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160**.** links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
55. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
56. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.
57. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.
58. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci.

2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.

59. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910. https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma.EMMA2.pdf.
60. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
61. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research,* 2018; 1 (2):08-14. https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf.
62. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
63. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.
64. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
65. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.
66. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.
67. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-108.
68. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.
69. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).

70. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
71. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
72. Moat SJ, George RS, Carling RS. Use of dried blood spot specimens to monitor patients with inherited metabolic disorders. International journal of neonatal screening. 2020;6(2):26.
73. Edelbroek PM, van der Heijden J, Stolk LM. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Therapeutic drug monitoring. 2009 ;31(3):327-336.
74. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.
75. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.
76. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.
77. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
78. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
79. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. Elite Journal of Public Health. 2024;2(1):8-22.
80. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. Elite Journal of Immunology. 2024;2(1):14-33.
81. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. Medicine. 2024;103(9):e37354.
82. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. Elite Journal of Immunology. 2024;2(1):1-3.
83. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. Elite Journal of Immunology. 2024;2(1):34-46.

84. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):46-58.
85. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. Elite Journal of Medicine. 2024;2(1):35-46.
86. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. Journal home page: http://www. journalijiar. com.;12(01).
87. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV. 2024;2(1):65-78.
88. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
89. ObeaguEI AA, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. Elite Journal of HIV. 2024;2(1):31-50.
90. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. Elite Journal of HIV. 2024;2(1):1-5.
91. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):25-36.
92. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Sciences. 2024;4(1):32-7.
93. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. Sciences. 2024;4(1):38-44.
94. Ghadrshenas A, Amor YB, Chang J, Dale H, Sherman G, Vojnov L, Young P, Yogev R, Child Survival Working Group of the Interagency Task Team on the Prevention and Treatment of HIV infection in Pregnant Women, Mothers and Children. Improved access to early infant diagnosis is a critical part of a child-centric prevention of mother-to-child transmission agenda. Aids. 2013;27: S197-205.
95. Adebimpe WO. Challenges facing early infant diagnosis of HIV among infants in resource poor settings. African Journal of Reproductive Health. 20131;17(1):1222-9.
96. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. Elite Journal of Health Science. 2024;2(1):33-42.
97. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. Elite Journal of Haematology. 2024;2(1):26-41.
98. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. Elite Journal of Medicine. 2024;2(2):104-15.
99. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology. 2024;2(1):47-64.

100. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. Elite Journal of HIV. 2024;2(2):1-7.
101. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health. 2024;2(1):52-61.
102. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. Elite Journal of Public Health. 2024;2(1):22-34.
103. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. Elite Journal of Nursing and Health Science. 2024;2(1):21-31.
104. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
105. Haleyur Giri Setty MK, Hewlett IK. Point of care technologies for HIV. AIDS research and treatment. 2014.
106. Aleku GA, Adoga MP, Agwale SM. HIV point-of-care diagnostics: meeting the special needs of sub-Saharan Africa. The Journal of Infection in Developing Countries. 2014;8(10):1231-1243.
107. Preiser W, Van Zyl GU. Pooled testing: A tool to increase efficiency of infant HIV diagnosis and virological monitoring. African Journal of Laboratory Medicine. 2020;9(2):1-7.
108. Deo S, Gallien J, Jónasson JO. Improving HIV early infant diagnosis supply chains in sub-Saharan Africa: Models and application to Mozambique. Available at SSRN 2511549. 2015.